On-the-road driving performance after use of the antihistamines mequitazine and l-mequitazine, alone and with alcohol
Objective Previous studies demonstrated that mequitazine produces mild sedation after single doses. Its enantiomer, l-mequitazine, has a stronger potency for the H1 receptor. The aim of the current study was to assess the effects of l-mequitazine and mequitazine, alone and with alcohol, on driving....
Gespeichert in:
| Veröffentlicht in: | Psychopharmacology 2016-09, Vol.233 (18), p.3461-3469 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3469 |
|---|---|
| container_issue | 18 |
| container_start_page | 3461 |
| container_title | Psychopharmacology |
| container_volume | 233 |
| creator | van der Sluiszen, N. N. J. J. M. Vermeeren, A. Jongen, S. Theunissen, E. L. van Oers, A. C. M. Van Leeuwen, C. J. Maret, A. Desforges, C. Delarue, A. Ramaekers, J. G. |
| description | Objective
Previous studies demonstrated that mequitazine produces mild sedation after single doses.
Its enantiomer, l-mequitazine, has a stronger potency for the H1 receptor. The aim of the current study was to assess the effects of l-mequitazine and mequitazine, alone and with alcohol, on driving.
Methods
Twenty-five healthy volunteers were treated with l-mequitazine 2.5, 5.0 and 10 mg, mequitazine 10 mg and placebo, alone and in combination with alcohol in a double-blind crossover design. Driving performance was assessed using the standardized highway driving test in normal traffic. Its primary measure is the Standard Deviation of the Lateral Position (SDLP). Secondary measures consisted of an auditory word learning test during driving, and subjective measures of driving performance.
Results
L-mequitazine 2.5 and 5.0 mg showed no effect on SDLP in the highway driving test, while SDLP significantly increased after l-mequitazine 10 mg (alone +1.59 cm; with alcohol +1.41 cm) and mequitazine 10 mg (with alcohol +1.17 cm). Alcohol significantly impaired all performance measures (SDLP +2.63 cm) but did not interact with the effects of treatment. Subjective measures indicated that participants were aware of the impairing effects of alcohol, but not of l-mequitazine and mequitazine.
Conclusion
L-mequitazine can be considered safe to drive in dosages of 2.5 and 5.0 mg. L-mequitazine 10 mg led to mild driving impairment. Alcohol impaired all performance measures and added to the effects of l-mequitazine and mequitazine. |
| doi_str_mv | 10.1007/s00213-016-4386-7 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4989021</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A470448025</galeid><sourcerecordid>A470448025</sourcerecordid><originalsourceid>FETCH-LOGICAL-c640t-53953f5668c827de673842b0bbd84651b1ad10a66ddd95e988c9552ce892b8b3</originalsourceid><addsrcrecordid>eNqNkl1rHCEUhqW0NNttf0BvitCbXNTU73FuCiH0CwK5yb046uwaZnSjMwntr4_DbtNNaaF6Ieec5xz15QXgLcFnBOPmY8GYEoYwkYgzJVHzDKwIZxRR3NDnYIUxY4gRoU7Aq1JucF1c8ZfghDZcKdLSFZivIpq2HuVkHHQ53IW4gTuf-5RHE62Hpp98hnPxMPWwktDEKWxDmcwYoi9w9LdzmMzPGtSSgwM6ynyAZkiHwn2YtjW0aZuG1-BFb4bi3xzONbj-8vn64hu6vPr6_eL8ElnJ8YQEawXrhZTKKto4LxumOO1w1znFpSAdMY5gI6VzrhW-Vcq2QlDrVUs71bE1-LQfu5u70Tvr45TNoHc5jCb_0MkE_bQSw1Zv0p3mrWoXadfg9DAgp9vZl0mPoVg_DCb6NBdNFBENpovO_4FS1RIpeUXf_4HepDnHKsRCEcXq5eI3tTGD1yH2qT7RLkP1OW8w5wrThTr7C1W382OwVfs-1PyTBrJvsDmVkn3_KAfBenGV3rtKV1fpxVW6qT3vjnV87PhlowrQPVBqKW58PvrRP6c-AC261wU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1811838905</pqid></control><display><type>article</type><title>On-the-road driving performance after use of the antihistamines mequitazine and l-mequitazine, alone and with alcohol</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>van der Sluiszen, N. N. J. J. M. ; Vermeeren, A. ; Jongen, S. ; Theunissen, E. L. ; van Oers, A. C. M. ; Van Leeuwen, C. J. ; Maret, A. ; Desforges, C. ; Delarue, A. ; Ramaekers, J. G.</creator><creatorcontrib>van der Sluiszen, N. N. J. J. M. ; Vermeeren, A. ; Jongen, S. ; Theunissen, E. L. ; van Oers, A. C. M. ; Van Leeuwen, C. J. ; Maret, A. ; Desforges, C. ; Delarue, A. ; Ramaekers, J. G.</creatorcontrib><description>Objective
Previous studies demonstrated that mequitazine produces mild sedation after single doses.
Its enantiomer, l-mequitazine, has a stronger potency for the H1 receptor. The aim of the current study was to assess the effects of l-mequitazine and mequitazine, alone and with alcohol, on driving.
Methods
Twenty-five healthy volunteers were treated with l-mequitazine 2.5, 5.0 and 10 mg, mequitazine 10 mg and placebo, alone and in combination with alcohol in a double-blind crossover design. Driving performance was assessed using the standardized highway driving test in normal traffic. Its primary measure is the Standard Deviation of the Lateral Position (SDLP). Secondary measures consisted of an auditory word learning test during driving, and subjective measures of driving performance.
Results
L-mequitazine 2.5 and 5.0 mg showed no effect on SDLP in the highway driving test, while SDLP significantly increased after l-mequitazine 10 mg (alone +1.59 cm; with alcohol +1.41 cm) and mequitazine 10 mg (with alcohol +1.17 cm). Alcohol significantly impaired all performance measures (SDLP +2.63 cm) but did not interact with the effects of treatment. Subjective measures indicated that participants were aware of the impairing effects of alcohol, but not of l-mequitazine and mequitazine.
Conclusion
L-mequitazine can be considered safe to drive in dosages of 2.5 and 5.0 mg. L-mequitazine 10 mg led to mild driving impairment. Alcohol impaired all performance measures and added to the effects of l-mequitazine and mequitazine.</description><identifier>ISSN: 0033-3158</identifier><identifier>EISSN: 1432-2072</identifier><identifier>DOI: 10.1007/s00213-016-4386-7</identifier><identifier>PMID: 27488192</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adult ; Alcohol ; Alcoholic beverages ; Antihistamines ; Automobile Driving ; Biomedical and Life Sciences ; Biomedicine ; Central Nervous System Depressants - pharmacology ; Comparative analysis ; Cross-Over Studies ; Dosage and administration ; Double-Blind Method ; Driving Under the Influence ; Ethanol - pharmacology ; Female ; Health aspects ; Healthy Volunteers ; Histamine ; Histamine H1 Antagonists - pharmacology ; Humans ; Male ; Middle Aged ; Motor vehicle driving ; Neurosciences ; Original Investigation ; Pharmacology/Toxicology ; Phenothiazines - pharmacology ; Psychiatry ; Psychological aspects ; Psychomotor Performance - drug effects ; Psychopharmacology ; Young Adult</subject><ispartof>Psychopharmacology, 2016-09, Vol.233 (18), p.3461-3469</ispartof><rights>The Author(s) 2016</rights><rights>COPYRIGHT 2016 Springer</rights><rights>Springer-Verlag Berlin Heidelberg 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c640t-53953f5668c827de673842b0bbd84651b1ad10a66ddd95e988c9552ce892b8b3</citedby><cites>FETCH-LOGICAL-c640t-53953f5668c827de673842b0bbd84651b1ad10a66ddd95e988c9552ce892b8b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00213-016-4386-7$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00213-016-4386-7$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,27903,27904,41467,42536,51298</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27488192$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van der Sluiszen, N. N. J. J. M.</creatorcontrib><creatorcontrib>Vermeeren, A.</creatorcontrib><creatorcontrib>Jongen, S.</creatorcontrib><creatorcontrib>Theunissen, E. L.</creatorcontrib><creatorcontrib>van Oers, A. C. M.</creatorcontrib><creatorcontrib>Van Leeuwen, C. J.</creatorcontrib><creatorcontrib>Maret, A.</creatorcontrib><creatorcontrib>Desforges, C.</creatorcontrib><creatorcontrib>Delarue, A.</creatorcontrib><creatorcontrib>Ramaekers, J. G.</creatorcontrib><title>On-the-road driving performance after use of the antihistamines mequitazine and l-mequitazine, alone and with alcohol</title><title>Psychopharmacology</title><addtitle>Psychopharmacology</addtitle><addtitle>Psychopharmacology (Berl)</addtitle><description>Objective
Previous studies demonstrated that mequitazine produces mild sedation after single doses.
Its enantiomer, l-mequitazine, has a stronger potency for the H1 receptor. The aim of the current study was to assess the effects of l-mequitazine and mequitazine, alone and with alcohol, on driving.
Methods
Twenty-five healthy volunteers were treated with l-mequitazine 2.5, 5.0 and 10 mg, mequitazine 10 mg and placebo, alone and in combination with alcohol in a double-blind crossover design. Driving performance was assessed using the standardized highway driving test in normal traffic. Its primary measure is the Standard Deviation of the Lateral Position (SDLP). Secondary measures consisted of an auditory word learning test during driving, and subjective measures of driving performance.
Results
L-mequitazine 2.5 and 5.0 mg showed no effect on SDLP in the highway driving test, while SDLP significantly increased after l-mequitazine 10 mg (alone +1.59 cm; with alcohol +1.41 cm) and mequitazine 10 mg (with alcohol +1.17 cm). Alcohol significantly impaired all performance measures (SDLP +2.63 cm) but did not interact with the effects of treatment. Subjective measures indicated that participants were aware of the impairing effects of alcohol, but not of l-mequitazine and mequitazine.
Conclusion
L-mequitazine can be considered safe to drive in dosages of 2.5 and 5.0 mg. L-mequitazine 10 mg led to mild driving impairment. Alcohol impaired all performance measures and added to the effects of l-mequitazine and mequitazine.</description><subject>Adult</subject><subject>Alcohol</subject><subject>Alcoholic beverages</subject><subject>Antihistamines</subject><subject>Automobile Driving</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Central Nervous System Depressants - pharmacology</subject><subject>Comparative analysis</subject><subject>Cross-Over Studies</subject><subject>Dosage and administration</subject><subject>Double-Blind Method</subject><subject>Driving Under the Influence</subject><subject>Ethanol - pharmacology</subject><subject>Female</subject><subject>Health aspects</subject><subject>Healthy Volunteers</subject><subject>Histamine</subject><subject>Histamine H1 Antagonists - pharmacology</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Motor vehicle driving</subject><subject>Neurosciences</subject><subject>Original Investigation</subject><subject>Pharmacology/Toxicology</subject><subject>Phenothiazines - pharmacology</subject><subject>Psychiatry</subject><subject>Psychological aspects</subject><subject>Psychomotor Performance - drug effects</subject><subject>Psychopharmacology</subject><subject>Young Adult</subject><issn>0033-3158</issn><issn>1432-2072</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqNkl1rHCEUhqW0NNttf0BvitCbXNTU73FuCiH0CwK5yb046uwaZnSjMwntr4_DbtNNaaF6Ieec5xz15QXgLcFnBOPmY8GYEoYwkYgzJVHzDKwIZxRR3NDnYIUxY4gRoU7Aq1JucF1c8ZfghDZcKdLSFZivIpq2HuVkHHQ53IW4gTuf-5RHE62Hpp98hnPxMPWwktDEKWxDmcwYoi9w9LdzmMzPGtSSgwM6ynyAZkiHwn2YtjW0aZuG1-BFb4bi3xzONbj-8vn64hu6vPr6_eL8ElnJ8YQEawXrhZTKKto4LxumOO1w1znFpSAdMY5gI6VzrhW-Vcq2QlDrVUs71bE1-LQfu5u70Tvr45TNoHc5jCb_0MkE_bQSw1Zv0p3mrWoXadfg9DAgp9vZl0mPoVg_DCb6NBdNFBENpovO_4FS1RIpeUXf_4HepDnHKsRCEcXq5eI3tTGD1yH2qT7RLkP1OW8w5wrThTr7C1W382OwVfs-1PyTBrJvsDmVkn3_KAfBenGV3rtKV1fpxVW6qT3vjnV87PhlowrQPVBqKW58PvrRP6c-AC261wU</recordid><startdate>20160901</startdate><enddate>20160901</enddate><creator>van der Sluiszen, N. N. J. J. M.</creator><creator>Vermeeren, A.</creator><creator>Jongen, S.</creator><creator>Theunissen, E. L.</creator><creator>van Oers, A. C. M.</creator><creator>Van Leeuwen, C. J.</creator><creator>Maret, A.</creator><creator>Desforges, C.</creator><creator>Delarue, A.</creator><creator>Ramaekers, J. G.</creator><general>Springer Berlin Heidelberg</general><general>Springer</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7QR</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160901</creationdate><title>On-the-road driving performance after use of the antihistamines mequitazine and l-mequitazine, alone and with alcohol</title><author>van der Sluiszen, N. N. J. J. M. ; Vermeeren, A. ; Jongen, S. ; Theunissen, E. L. ; van Oers, A. C. M. ; Van Leeuwen, C. J. ; Maret, A. ; Desforges, C. ; Delarue, A. ; Ramaekers, J. G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c640t-53953f5668c827de673842b0bbd84651b1ad10a66ddd95e988c9552ce892b8b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Alcohol</topic><topic>Alcoholic beverages</topic><topic>Antihistamines</topic><topic>Automobile Driving</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Central Nervous System Depressants - pharmacology</topic><topic>Comparative analysis</topic><topic>Cross-Over Studies</topic><topic>Dosage and administration</topic><topic>Double-Blind Method</topic><topic>Driving Under the Influence</topic><topic>Ethanol - pharmacology</topic><topic>Female</topic><topic>Health aspects</topic><topic>Healthy Volunteers</topic><topic>Histamine</topic><topic>Histamine H1 Antagonists - pharmacology</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Motor vehicle driving</topic><topic>Neurosciences</topic><topic>Original Investigation</topic><topic>Pharmacology/Toxicology</topic><topic>Phenothiazines - pharmacology</topic><topic>Psychiatry</topic><topic>Psychological aspects</topic><topic>Psychomotor Performance - drug effects</topic><topic>Psychopharmacology</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van der Sluiszen, N. N. J. J. M.</creatorcontrib><creatorcontrib>Vermeeren, A.</creatorcontrib><creatorcontrib>Jongen, S.</creatorcontrib><creatorcontrib>Theunissen, E. L.</creatorcontrib><creatorcontrib>van Oers, A. C. M.</creatorcontrib><creatorcontrib>Van Leeuwen, C. J.</creatorcontrib><creatorcontrib>Maret, A.</creatorcontrib><creatorcontrib>Desforges, C.</creatorcontrib><creatorcontrib>Delarue, A.</creatorcontrib><creatorcontrib>Ramaekers, J. G.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Psychopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van der Sluiszen, N. N. J. J. M.</au><au>Vermeeren, A.</au><au>Jongen, S.</au><au>Theunissen, E. L.</au><au>van Oers, A. C. M.</au><au>Van Leeuwen, C. J.</au><au>Maret, A.</au><au>Desforges, C.</au><au>Delarue, A.</au><au>Ramaekers, J. G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>On-the-road driving performance after use of the antihistamines mequitazine and l-mequitazine, alone and with alcohol</atitle><jtitle>Psychopharmacology</jtitle><stitle>Psychopharmacology</stitle><addtitle>Psychopharmacology (Berl)</addtitle><date>2016-09-01</date><risdate>2016</risdate><volume>233</volume><issue>18</issue><spage>3461</spage><epage>3469</epage><pages>3461-3469</pages><issn>0033-3158</issn><eissn>1432-2072</eissn><abstract>Objective
Previous studies demonstrated that mequitazine produces mild sedation after single doses.
Its enantiomer, l-mequitazine, has a stronger potency for the H1 receptor. The aim of the current study was to assess the effects of l-mequitazine and mequitazine, alone and with alcohol, on driving.
Methods
Twenty-five healthy volunteers were treated with l-mequitazine 2.5, 5.0 and 10 mg, mequitazine 10 mg and placebo, alone and in combination with alcohol in a double-blind crossover design. Driving performance was assessed using the standardized highway driving test in normal traffic. Its primary measure is the Standard Deviation of the Lateral Position (SDLP). Secondary measures consisted of an auditory word learning test during driving, and subjective measures of driving performance.
Results
L-mequitazine 2.5 and 5.0 mg showed no effect on SDLP in the highway driving test, while SDLP significantly increased after l-mequitazine 10 mg (alone +1.59 cm; with alcohol +1.41 cm) and mequitazine 10 mg (with alcohol +1.17 cm). Alcohol significantly impaired all performance measures (SDLP +2.63 cm) but did not interact with the effects of treatment. Subjective measures indicated that participants were aware of the impairing effects of alcohol, but not of l-mequitazine and mequitazine.
Conclusion
L-mequitazine can be considered safe to drive in dosages of 2.5 and 5.0 mg. L-mequitazine 10 mg led to mild driving impairment. Alcohol impaired all performance measures and added to the effects of l-mequitazine and mequitazine.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>27488192</pmid><doi>10.1007/s00213-016-4386-7</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0033-3158 |
| ispartof | Psychopharmacology, 2016-09, Vol.233 (18), p.3461-3469 |
| issn | 0033-3158 1432-2072 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4989021 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Adult Alcohol Alcoholic beverages Antihistamines Automobile Driving Biomedical and Life Sciences Biomedicine Central Nervous System Depressants - pharmacology Comparative analysis Cross-Over Studies Dosage and administration Double-Blind Method Driving Under the Influence Ethanol - pharmacology Female Health aspects Healthy Volunteers Histamine Histamine H1 Antagonists - pharmacology Humans Male Middle Aged Motor vehicle driving Neurosciences Original Investigation Pharmacology/Toxicology Phenothiazines - pharmacology Psychiatry Psychological aspects Psychomotor Performance - drug effects Psychopharmacology Young Adult |
| title | On-the-road driving performance after use of the antihistamines mequitazine and l-mequitazine, alone and with alcohol |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T11%3A43%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=On-the-road%20driving%20performance%20after%20use%20of%20the%20antihistamines%20mequitazine%20and%20l-mequitazine,%20alone%20and%20with%20alcohol&rft.jtitle=Psychopharmacology&rft.au=van%20der%20Sluiszen,%20N.%20N.%20J.%20J.%20M.&rft.date=2016-09-01&rft.volume=233&rft.issue=18&rft.spage=3461&rft.epage=3469&rft.pages=3461-3469&rft.issn=0033-3158&rft.eissn=1432-2072&rft_id=info:doi/10.1007/s00213-016-4386-7&rft_dat=%3Cgale_pubme%3EA470448025%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1811838905&rft_id=info:pmid/27488192&rft_galeid=A470448025&rfr_iscdi=true |